A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

June 5, 2023

Primary Completion Date

December 16, 2028

Study Completion Date

December 16, 2028

Conditions
Anemia
Interventions
BIOLOGICAL

Luspatercept

Specified dose on specified days

Trial Locations (9)

110029

Local Institution - 0001, New Delhi

110085

Local Institution - 0010, Delhi

160012

Local Institution - 0004, Chandigarh

380009

Local Institution - 0002, Ahmedabad

400012

Local Institution - 0008, Mumbai

500034

Local Institution - 0006, Hyderabad

560027

Local Institution - 0003, Bangalore

700014

Local Institution - 0007, Kolkata

781032

Local Institution - 0005, Assam

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY